The Patient Protection and Affordable Care Act of 2010 established a new tax credit and cash grant program for certain small and mid-sized companies that engage in a “qualifying therapeutic discovery project.” This tax incentive provides a significant financial opportunity for smaller biotechnology companies. The credit equals 50 percent of the aggregate costs paid or incurred in a tax year for expenses necessary for, and directly related to, the conduct of a qualifying therapeutic discovery. In lieu of the credit, a taxpayer can request a grant of 50 percent of the qualified investment. This alternative may be useful for companies that may not have taxable income that can be offset by a credit. The credits and grants are available only with respect to expenditures made in a taxable year beginning in 2009 or 2010 and can only be requested by a company with 250 or fewer employees at the time of application. The total amount of credits and grants allocated to this program is capped at $1 billion. The specific provisions of this tax credit are codified in new Internal Revenue Code § 48D.
A qualifying therapeutic discovery project is designed to accomplish any of the following:
The credit or grant is not available to the following costs:
The Secretary of the Treasury, in conjunction with the Department of Health and Human Services, is required to establish a program to consider and certify qualified investments within 60 days of enactment (i.e. no later than May 21, 2010). Taxpayers must obtain certification for qualifying investments by applying with the Secretary. Once the program is established, the Secretary of the Treasury has 30 days from the date an application for a credit is submitted to approve or deny the application. The identity of all entities that receive a qualifying therapeutic discovery project credit will be publicly disclosed.
In determining qualifying projects, the Secretary will consider only those projects that show reasonable potential to:
In addition to these qualifications, the Secretary will also take into consideration projects that have the greatest potential to:
There are several rules that prevent double tax benefits, including bonus depreciation, basis adjustment, research and development credits, and clinical testing expenses for certain drugs for rare diseases or conditions.
Due to the limited availability of funds, it is important for smaller companies in the biotech industry to begin evaluating their current and planned projects to determine which, if any of their projects could qualify for the credit, and how to document and quantify their expenditures to request certification if they are interested in taking advantage of this new tax incentive.